iNFixion Bioscience completes NIH I-Corps™ commercialization program
The core team at iNFixion Bioscience has successfully completed the prestigious NIH I-Corps™ commercialization program. In addition to a commercialization curriculum, the program included teh requirement of conducting interviews with over 100 people from across the NF1 and Rare Drug ecosystems. These interviews included: Adults with NF1, NF1 parents, NF clinic directors and specialists, rare disease and pharma professionals, and potential investment partners. Using the I-Corps structure and methodology, the Infixion core team was able to crystallize its vision, improve their understanding of adult vs. pediatric requirements, establish a priority in terms of targeting NF1 symptoms, and solidify a tentative decision to pursue a companion biomarker program. The core team members also learned valuable presentation and teamwork skills while under the stress of conducting 106 half-hour interviews in just 7 weeks.
To learn more about I-Corps™ click here: